Trials with anti-mesothelin CARs and anti-cMet CARs against malignant pleural mesothelioma (NCT01355965), metastatic pancreatic ductal adenocarcinoma (NCT01897415) and metastatic triple-negative breast cancer (NCT01837602) have been completed. The gene discussed is MSLN; the disease is malignant pleural mesothelioma.